Loading clinical trials...
Loading clinical trials...
A Phase 2 Single Arm Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients
Conditions
Interventions
Elotuzumab
Lenalidomide
+1 more
Locations
29
United States
Acrc/Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
Highland Oncology Group
Fayetteville, Arkansas, United States
Comprehensive Blood And Cancer Center
Bakersfield, California, United States
California Cancer Associates for Research and Excellence
Encinitas, California, United States
Compassionate Cancer Res Grp
Fountain Valley, California, United States
Robert A. Moss, Md Facp, Inc.
Fountain Valley, California, United States
Start Date
March 8, 2014
Primary Completion Date
June 30, 2016
Completion Date
July 11, 2018
Last Updated
July 16, 2019
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Bristol-Myers Squibb
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions